PatientsLikeMe has unveiled a suite of services for pharmaceutical companies that allows them to collaborate with patients on the design of clinical trials and other research.
PatientsLikeMe has unveiled a suite of services for pharmaceutical companies that allows them to collaborate with patients on the design of clinical trials and other research. The announcement was made at the 50th annual meeting of the Drug Information Association (DIA) in San Diego, where global leaders in drug development and regulation are discussing new ways to accelerate the development of patient-centered health solutions.
Vice President of Innovation Paul Wicks, Ph.D. said that with more than 250,000 members reporting on their experiences with 2,000 diseases, PatientsLikeMe has transformed the way patients can shape research. “We’ve nurtured an open, data-sharing environment where members share their experiences to live better, and built a foundation for pharma-patient partnerships that can truly advance medicine. By listening to patients, we can create actionable insights that optimize the design of trial protocols and bring about better treatments, faster.”
The launch comes as results from a March 2014 survey of PatientsLikeMe members reveal just how broken the trial process is, and how eager patients are to help fix it. Members were asked about their attitudes toward, experiences with and criteria for participating in clinical trials. Of 1,621 survey respondents:
The full survey results are being presented at DIA’s Professional Poster Session at location T44 on Tuesday, June 17, 2014.
PatientsLikeMe announced three services at DIA:
For more information, visit
www.patientslikeme.com/services
.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.